Initial LAG-3 combo data presented
Prima BioMed has presented encouraging early signs of efficacy from the TACTI-mel trial of IMP321 in combination with Keytruda, with one of the six...
66 Views
AIPAC Phase IIb starts randomized component
Prima BioMed maintains its leadership in LAG-3 immunotherapies with the initiation of the randomized Phase IIb component of the AIPAC trial of...
74 Views
AIPAC Phase IIb starts randomised component
Prima BioMed maintains its leadership in LAG-3 immunotherapies with the initiation of the randomised Phase IIb component of the AIPAC trial of...
73 Views